How to help high prescribers expand their use of Brintellix® into the elderly sub-population, with Madeleine Weinert (Senior Global Brand Manager, Brintellix) and Michael Adair (Global Medical Advisor).
In today's episode, we're building on the previous podcast episode which was all about the MEMORY Study - a 12-week study with vortioxetine in patients with Major Depressive Disorder (MDD) and early-stage dementia.
With the help of brilliant co-hosts Madeleine Weinert (Senior Global Brand Manager, Brintellix) and Michael Adair (Global Medical Advisor), we'll become more familiar with the main findings from the MEMORY Study and talk about how to apply these strategically in conversations with high prescribing psychiatrists (and other prescriber types seeing many elderly patients), to help them see more opportunities with Brintellix in patient populations beyond Detached Debbie in MDD.
Key Takeaways:
[00:05] Introduction to the Brintellix high prescriber strategy and the MEMORY study
[02:15] Overview of MDD in the elderly sub-population
[03:28] Using the MEMORY Study when talking to high prescribers
[08:20 ] The high prescriber journey
[11:07 ] Summary: The elderly population is a key focus for the growth of Brintellix amongst high prescribers; we can use the MEMORY study to encourage the use of Brintellix in the elderly population; by helping high prescribers to expand their use of Brintellix beyond Detached Debbie patient types, we will help more and more patients benefit from Brintellix.
Resources:
